Riskpilot← Back to searchSign inGet full accessUGLX Research AB
ABActiveOrg 5592414642Igelösa 373Research and experimental development on natural sciences and engineering · NACE 7210Est. 20200 employees
Revenue 2024
SEK 500K
EBITDA margin
61.5%
+741% vs 2023
Equity ratio
36.7%
Financial strength
Net profit 2024
SEK 145K
+189% vs 2023
| Revenue | SEK 500K | — |
| EBITDA | SEK 308K | +741% |
| Net profit | SEK 145K | +189% |
| Total assets | SEK 1,4M | +32% |
| Equity | SEK 527K | +38% |
| Employees | 0 | — |
Legal name
UGLX Research AB
Org number
5592414642
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
10 februari 2020
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Bolaget ska bedriva forskning och utvecklingsarbete föresträdesvis inom hälsovård samt därmed förenlig verksamhet.
Address
Igelösa 373
Email
ludvig.sjoberg@igelosa.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 500 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −3 | −2 | −72 | −48 | 308 |
| Depreciation & amort. | −4 | −17 | −73 | −87 | −102 |
| EBIT | −7 | −19 | −145 | −135 | 206 |
| Net financials | −2 | −7 | −24 | −28 | −61 |
| Profit before tax | −9 | −26 | −169 | −163 | 145 |
| Tax | −0 | −0 | −0 | −0 | — |
| Net profit | −9 | −26 | −169 | −163 | 145 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 141 | 1 115 | 946 | 1 093 | 1 438 |
| Equity | 41 | 315 | 146 | 383 | 527 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 100 | 800 | 800 | 710 | 910 |
| Total debt | 100 | 800 | 800 | 710 | 910 |
EBITDA margin
61.5%
This company
15.8%
Market median
+289% vs market
20202024
Equity ratio
36.7%
This company
38.2%
Market median
+4% vs market
20202024
Return on equity
27.4%
This company
18.4%
Market median
+49% vs market
20202024
Net profit margin
29.0%
This company
8.1%
Market median
+258% vs market
20202024
Asset turnover
0.35×
This company
1.12×
Market median
-69% vs market
20202024
Debt / equity
1.73×
This company
0.62×
Market median
-179% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-02-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
BO Chief Auditor | Chief Auditor | 2025 |
| Former (1) | ||
JT Chief Auditor | Chief Auditor | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of UGLX Research AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Tomas Ahlgren | Chief Auditor | 0 companies |
| Birger Ola Mattias Kristensson | Chief Auditor | 0 companies |
| Semmy Rülf | Chairman | 0 companies |
| Axel Nils Gabriel Gyllenkrok | Board of Directors | 0 companies |
| Karl Ludvig Trygve Sjöberg | Deputy Board Member | 0 companies |
| Ådne Steen | Board of Directors | 0 companies |